The latest News

Keep in Touch with Cellestia.

cellestia-biotech-hero

The latest News

Keep in Touch with Cellestia.

March 2019

American Association for Cancer Research Meeting

Cellestia selected for an oral presentation on CB-103 by Dr. Raj Lehal, Chief Scientific Officer, at the Preclinical Drug Development session of the American Association for Cancer Research Meeting (Atlanta, March 29–April 3).

February 2019

IND accepted by the FDA

On Feb. 4th, Cellestia received the green light from the FDA for its Investigational New Drug Application (IND). The FDA completed its review, and concluded that Cellestia can proceed with its clinical investigation of CB-103 in tumors driven by an oncogenic NOTCH signaling pathway.

December 2018

Cellestia Biotech AG secures CHF 20 million in Series A funding

Cellestia announced today the close of a CHF 20 million Series A financing round. The financing will accelerate Cellestia’s ongoing clinical program, and advance its innovative R&D pipeline.
To read Cellestia’s press release click here.

Archive